BRIEF published on 03/10/2026 at 09:05, 6 days 1 hour ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 6 days 1 hour ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 7 days 3 hours ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
BRIEF published on 03/09/2026 at 07:35, 7 days 3 hours ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
PRESS RELEASE published on 03/09/2026 at 07:30, 7 days 3 hours ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 26 days 3 hours ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 26 days 3 hours ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 26 days 3 hours ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 1 month 6 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
BRIEF published on 02/10/2026 at 07:35, 1 month 6 days ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
Published on 03/15/2026 at 23:25, 11 hours 13 minutes ago Tunkillia 'Phase 2' Resource Upgrade Drilling Begins
Published on 03/15/2026 at 18:00, 16 hours 38 minutes ago SEG Announced 2025 Annual Results Initiating First Special Dividend Distribution Payout Ratio Reached 88% Newly Signed Orders Exceeded RMB100-Billion Mark for the Second Consecutive Year
Published on 03/13/2026 at 23:00, 2 days 11 hours ago CORRECTION FROM SOURCE: EV Nickel Announces Maiden Mineral Resource Estimate for Gemini North Nickel Zone
Published on 03/13/2026 at 23:00, 2 days 11 hours ago Redwood AI Announces Platform Name Change and Appointment of Dr. Mark Dybul as Public Safety & Defense Advisor
Published on 03/13/2026 at 21:30, 2 days 13 hours ago Alset AI Announces Closing of Shares for Debt Transaction
Published on 03/16/2026 at 10:20, 18 minutes ago EightSix Launches Brand Studio: The World's First Brand Music Intelligence System
Published on 03/16/2026 at 10:15, 23 minutes ago NVision and Aarhus University Awarded Innovation Fund Denmark Grant to Advance Clinical Translation of Quantum-Enhanced MRI
Published on 03/16/2026 at 10:05, 33 minutes ago AliExpress Anniversary Sale Hits up to 90% Off as Brand+ Channel Surges with Exclusive Tech Debuts and Price Guarantee
Published on 03/16/2026 at 10:00, 38 minutes ago REPLOID launches crowdfinancing campaign on Invesdor
Published on 03/16/2026 at 09:59, 39 minutes ago EQS-Adhoc: IBU-tec advanced materials AG publishes planning: Revenue expectation of at least EUR 120-140 million in 2030 and EUR 37- 39 million for 2026
Published on 03/16/2026 at 08:30, 2 hours 8 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 14 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 16 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 3 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 16 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
